Nevis Brands may have cracked the code to a successful cannabis beverage (CSE:NEVI)
https://www.proactiveinvestors.com/companies/news/1025172/nevis-brands-may-have-cracked-the-code-to-a-successful-cannabis-beverage-1025172.html

Nevis Brands announces partnership with Blaze Life to launch Major brand in California (CSE:NEVI)

Nevis Brands locks in license agreement with Blaze Life Holdings
https://themarketherald.ca/nevis-brands-locks-in-license-agreement-with-blaze-life-holdings-2023-10-05/

Big News>> NEVIS BRANDS INC. Announces Licensing Agreement and Expansion of Major™ brands to California (CSE: NEVI)

https://www.newswire.ca/news-releases/nevis-brands-inc-announces-licensing-agreement-and-expansion-of-major-tm-brands-to-california-811529755.html

Cannabis Stocks to Benefit from Impending USA Legislation
https://10xalerts.com/cannabis-stocks-to-benefit-from-impending-usa-legislation/

Nevis Brands announces big expansion of Major Brand in Nevada (CSE: NEVI)

NEVIS BRANDS INC. Announces Expansion of Major™ brands to Nevada

http://www.newswire.ca/en/releases/archive/September2023/06/c2478.html

Pascal Biosciences Inc. changed to Nevis Brands Inc.:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

https://www.pascalbiosciences.com/pascal-biosciences-signs-term-sheet-for-acquisition-of-thc-essentials/

https://finance.yahoo.com/news/iiroc-trading-halt-pas-161100530.html

Trading halt pending news.

Thanks TSR.
Still a undiscovered stock IMO.

Check out this video released today. I believe Pascal Biosciences going to trials for this antibody-drug.

Pascal Biosciences : Awarded NIH Grant For Leukemia Program
June 8, 2021- Pascal Biosciences Inc. ('Pascal' or the 'Company') (TSXV:PAS) (OTC:PSCBF), has been awarded a grant of US$343,750 from the National Cancer Institute of the US National Institutes of Health (NIH). This two-year award will fund development of Pascal's antibody drug for Acute Lymphoblastic Leukemia (ALL), which is the most common childhood leukemia.

Pascal is the first to advance an antibody targeting the highly leukemia-specific protein, VpreB, for treating ALL. 'This grant validates our scientific efforts and will accelerate development of a new treatment for leukemia patients', stated CEO Patrick Gray. 'The exquisite specificity of our antibody will eliminate many of the hazards of current therapies for ALL. This grant will enable Pascal to bring our product into clinical trials.'

More than 6000 patients are diagnosed with Acute Lymphoblastic Leukemia (ALL) each year in Canada and the US. About half of ALL patients are adults and half are children, which makes this disease the most common type of childhood leukemia. Pascal's drug will be eligible for orphan drug designation, which can enable financial incentives and a seven year marketing exclusivity. Pascal has filed for patent protection for its ALL treatment. While the number of patients with ALL is relatively small, the market potential for Pascal's drug could be significant. Other cancer products for orphan diseases have proven to be financially successful, selling over $1B each year.

ABOUT ACUTE LYMPHOBLASTIC LEUKEMIA

ALL arises as a consequence of dysregulated proliferation of early-stage B cells. The current treatment for ALL-a chemotherapeutic regimen with four toxic drugs-has not changed in over 40 years. This regimen can be quite effective (85% success in children, 50% in adults). However, short- and long-term side effects can be devastating: young patients may have cognitive or developmental problems and frequently develop additional cancers 20 years after treatment, while older patients tend to have great difficulty coping with side effects. Pascal is developing monoclonal antibodies specific for a cell surface protein found only on ALL cells and on the early-stage cells from which ALL originates. This specificity spares the normal, mature B lymphocytes needed for protecting the patient from infection. Pascal's lead antibody for drug development binds the tumor target with high affinity and has good biophysical properties for expedient drug development. Patients treated with Pascal's drug will have the benefit of a highly targeted treatment and will also avoid the detrimental side effects of chemotherapy. The NIH grant, which covers both research and administrative costs for Pascal's program over a period of two years, will validate a drug product for clinical development to treat this challenging leukemia.

ABOUT PASCAL BIOSCIENCES INC.

Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. In addition to a targeted therapy for acute lymphoblastic leukemia, Pascal is developing treatments for cancer and cannabinoid-based therapeutics. Pascal's leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy which is being developed collaboratively with SoRSE Technology.

To learn more, visit: https://www.pascalbiosciences.com/.

On Behalf of the Board of Directors
Dr. Patrick W. Gray, CEO

Company Contact:
Mark van der Horst, President
Investors:
invest@pascalbiosciences.com
Tel: 206-221-3443

Interesting move to bring a capital markets guy on board as President. From a shareholder perspective, I like the idea of Pascal working to increase the profile of the company, both in Canada and U.S...

From the news, it would appear Pascal is going to get serious to expanding their shareholder base to include more US investors. I think this is a really positive move by the company.

Pascal Biosciences Announces New OTC Markets Trading Symbol PSCBF
Wed, June 2, 2021

VANCOUVER, BC / ACCESSWIRE / Pascal Biosciences Inc. ("Pascal" or the "Company") (TSXV:PAS)(OTC PINK:PSCBF, previously BIMUF), has today received a new Over The Counter (OTC) trading symbol following acceptance of Form 211 by the US Financial Industry Regulatory Authority (FINRA). The new symbol is PSCBF and better reflects the company name PaSCal Biosciences.

In addition, Pascal announced the Board of Directors has appointed Mark van der Horst as President. Mr. van der Horst has been the president of Gale Capital Corporation (Gale) since 1993. Gale has worked with numerous public companies in both Canada and the United States as a capital markets advisor. Most recently, Mark was CEO of two recently listed CSE companies, EyeFi Group Technologies Inc. (EGTI) and EonX Technologies Inc. (EONX) and was instrumental in their organization, listing and financing.

"We are making a concerted effort to increase our corporate communications in both Canada and the US. Further to that point, we are excited to welcome Mark van der Horst onboard as President. Mr. van der Horst brings over 30 years of North American capital markets experience and will be instrumental in creating greater investor awareness for Pascal." said CEO Patrick Gray.

FINRA is the US regulator responsible for OTC markets including the OTCBB and Pink Sheets. A company must file Form 211 with FINRA to comply with SEC Rule 15c2-11, which covers the requirements necessary for the initiation of electronic quotation of securities in the OTC Markets.

The completed Form 211 provides basic corporate information for review by FINRA.

ABOUT PASCAL BIOSCIENCES INC.

Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics. Pascal's leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy which is being developed collaboratively with SoRSE Technology.

To learn more, visit: https://www.pascalbiosciences.com/.

On Behalf of the Board of Directors
Dr. Patrick W. Gray, CEO

Company Contact:
Dr. Patrick Gray

Investors:
invest@pascalbiosciences.com
Tel: 206-221-3443

New US ticker

https://www.pascalbiosciences.com/news/

Effective June 1,2021 BIMUF will change to PSCBF:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Bid/ask now showing on TDA. That’s a new one.

https://finance.yahoo.com/news/pascal-biosciences-inc-closes-second-020000797.html

Ho boy!!!


https://finance.yahoo.com/news/pascal-biosciences-discovers-cannabinoid-combats-113000586.html

https://mailchi.mp/84e9772b6136/pascal-biosciences-announces-formation-of-clinical-advisory-board?e=4e851ed762

https://mailchi.mp/9a6d41c0e2f2/pascal-biosciences-partners-with-mitacs-to-support-innovative-cancer-research-at-university-of-british-columbia?e=4e851ed762

Pascal Biosciences Commences Cannabinoid Testing of Human Volunteers and Patients


VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, January 24, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the testing of cannabinoids in human subjects for their immune stimulatory program in cancer. Furthermore, the company has filed an international patent application to protect this work for future therapeutic indications.

Since discovering cannabinoids that can stimulate the immune system, Pascal has extensively studied many different cannabinoids in a variety of immune stimulatory assays. More than 375 cannabinoids from numerous sources have been examined, including natural cannabinoids from Cannabis (known as phytocannabinoids), synthetic cannabinoids prepared by chemists, and endocannabinoids naturally found in the human body. Specific natural cannabinoids have been identified that have potent activity in immune assays and also have a good safety profile.

“Our laboratory experiments have been very encouraging and suggest a potential to enhance the activity of cancer drugs. Cannabinoids stimulate the immune system and should work in concert with currently approved therapeutics”, said Dr. Patrick Gray, CEO of Pascal. “Human subject testing of cannabinoids has already been initiated. We plan to test both healthy volunteers and patients with cancer. Our first volunteer and our first patient with cancer have been treated to examine safety and pharmacology. We will extend these studies during the coming year with a potent cannabinoid for determination of its immune stimulatory activity. We will be testing cancer patients undergoing treatment with checkpoint inhibitors. We believe this work will be of great interest to patients, oncologists, and companies focused on cannabinoid therapeutics.”

In order to protect future efforts, Pascal has filed a patent on these discoveries. This intellectual property protection secures Pascal’s striking discovery that certain cannabinoids increase the immunogenicity of cancer cells. Advanced cancers prevail in part because they become invisible to the immune system. Restoring immunodetection of these cancers promises to arrest or eliminate the tumors, especially when combined with agents that depend upon immune recognition, such as immune checkpoint inhibitors.

Pascal’s patent application is covered by the Patent Cooperation Treaty that includes 151 countries and covers all major pharmaceutical markets worldwide. “This international patent application provides protection of our groundbreaking discoveries and is a testament to the novel scientific research of Pascal. This work may offer a transformative approach to improving immunotherapy,” said Dr. Patrick Gray, CEO of Pascal. “We look forward to further advancing our promising cannabinoid research efforts in both the laboratory and the clinic in 2019.”

Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs


VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, November 28, 2018 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the strengthening of its leadership team with the appointments of seasoned executives in therapeutic and business development. These include Kevin M. Egan, MBA, Vice President Business Development, Thomas Deckwerth, PhD, Vice President Therapeutic Development, and Larry W. Tjoelker, PhD, Vice President Research.

“We are pleased to have Kevin, Tom, and Larry as members of the senior leadership team at Pascal. Their extensive experience is invaluable as we advance our leading cannabinoid-based programs and explore strategic opportunities,” said Dr. Patrick Gray, CEO of Pascal. “This great team has been responsible for the discovery and development of numerous drugs, both through clinical development and partnering.”
Mr. Egan brings over 30 years of experience in the biotechnology industry with a proven track record of negotiating partnering, licensing, and outsourcing agreements. Beginning his career at Amgen, he helped develop and launch Epogen and Neupogen. Mr. Egan also worked for ICOS Corporation where he helped in the discovery and development of Cialis. He was responsible for building and managing the profitable ICOS biologics contract manufacturing business which was later acquired by CMC Biologics. He served as Vice President, Business Development for CMC Biologics where he led US Business Development efforts, and President of Borealis Biotechnology an international business development consulting firm. Mr. Egan received an MBA from the University of Washington, and a Masters in Biochemistry and Molecular Biology from UC Santa Barbara.
Dr. Thomas Deckwerth has 20 years of industrial experience in the research and development of therapeutics and medical devices. Prior to Pascal, Dr. Deckwerth was Vice President of Cancer Drug Development and Vice President of Product Development at Presage Biosciences where he led optimization and clinical drug product manufacturing projects. He was one of the first employees at Ikaria, Inc., later acquired by Mallinckrodt Pharmaceuticals. As Senior Director of Biological Chemistry, he led and managed therapeutics and diagnostics projects in the critical care space. Previously he was Section Head of Cellular Pharmacology at Idun Pharmaceuticals where he worked in collaborations with Novartis on caspase inhibitors for stroke and with Abbott Laboratories in the development of bcl2/bclxL and IAP antagonists for cancer indications until the acquisition of the company by Pfizer. He received his PhD in neuroscience at Washington University School of Medicine.

Dr. Tjoelker has over 25 years of research experience in the biotechnology industry, particularly in drug discovery for immunology and oncology. Prior to joining Pascal, Dr. Tjoelker was at public clinical-stage biotechs including ICOS, MacroGenics, and Omeros. During his 11-year tenure at ICOS Corporation, he cloned genes for inflammatory mediators which entered late stage clinical trials. As Director of Cancer Discovery at MacroGenics, Dr. Tjoelker and his team discovered 50 new cancer targets for monoclonal antibody therapy. He has also served as Director of Science at Omeros Corp. where his team discovered the first functional monoclonal antibodies against a proinflammatory complement cascade protease. Dr. Tjoelker received his PhD at the University of Michigan.

http://www.cannabisfn.com/cfn-medias-exclusive-interview-pascal-biosciences/

New volume today. Nice!

.240067 hmmm? Why would MM sell 5000 shares for 8% less. I cant go more than 4 digits so this isn't retail unless other retail can trade to 6 digits. HHMMM???

Back on radar as this should be! Great news!

Very Nice News!

https://globenewswire.com/news-release/2018/06/18/1525788/0/en/Pascal-Biosciences-Receives-DEA-Schedule-I-License-for-Cannabinoid-Development-and-Renews-UBC-Collaboration.html

And here I sit. Alls good. Nice and easy!

Nice base setting up.

And back down.

Wonder what today brings?

Well that was a fun close.

Hmmm. Volume. ?

Ahh. Peace and quite from the bicker boards.

Looks like a up and comer.

News

http://www.globenewswire.com/news-release/2017/09/11/1117513/0/en/Pascal-Biosciences-Acquires-Technology-to-Treat-Leukemia-from-the-University-of-New-Mexico.html

Very good they came from here...

https://www.canadianinsider.com/company?menu_tickersearch=PAS%20%7C%20Pascal%20Biosciences

Looked like a 100,000 share splash into this still pond today.